Clinical trial
Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults With Angelman Syndrome
NCT06914609 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults With Angelman Syndrome
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 10, 2025
- Completion date
- April 30, 2030
- Enrollment
- 156 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.